Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol MRI for Placental Lesions in Fetal Growth Restriction
NCT04839185Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Apr 2021
- Primary completion
- Oct 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferumoxytol in fetal growth restriction (FGR), sponsored by University of Wisconsin–Madison. Primary endpoints: Number of Participants for Which Intervillous Placental Blood is Detected at 1 week, Number of Participant for Which Placental Lesions Are Detected at 1 week and 1 more. Started Apr 2021; status: completed.
02
Drugs
ferumoxytol
03
Conditions
fetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT04839185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839185.